Literature DB >> 22129992

Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets.

Joon-Il Jun1, Lester F Lau.   

Abstract

Members of the CCN family of matricellular proteins are crucial for embryonic development and have important roles in inflammation, wound healing and injury repair in adulthood. Deregulation of CCN protein expression or activities contributes to the pathobiology of various diseases - many of which may arise when inflammation or tissue injury becomes chronic - including fibrosis, atherosclerosis, arthritis and cancer, as well as diabetic nephropathy and retinopathy. Emerging studies indicate that targeting CCN protein expression or signalling pathways holds promise in the development of diagnostics and therapeutics for such diseases. This Review summarizes the biology of CCN proteins, their roles in various pathologies and their potential as therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22129992      PMCID: PMC3663145          DOI: 10.1038/nrd3599

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  218 in total

1.  Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation.

Authors:  A M Bleau; N Planque; N Lazar; D Zambelli; A Ori; T Quan; G Fisher; K Scotlandi; B Perbal
Journal:  J Cell Biochem       Date:  2007-08-15       Impact factor: 4.429

2.  Expression of tumor-promoting Cyr61 is regulated by hTRA2-β1 and acidosis.

Authors:  Marc Hirschfeld; Markus Jaeger; Emanuele Buratti; Cristiana Stuani; Johannes Grueneisen; Gerald Gitsch; Elmar Stickeler
Journal:  Hum Mol Genet       Date:  2011-03-29       Impact factor: 6.150

3.  Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes.

Authors:  Takashi Nishida; Satoshi Kubota; Eriko Aoyama; Danilo Janune; Azusa Maeda; Masaharu Takigawa
Journal:  Endocrinology       Date:  2011-09-13       Impact factor: 4.736

4.  Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis.

Authors:  Nadja Dornhöfer; Suzanne Spong; Kevin Bennewith; Ali Salim; Stephen Klaus; Neeraja Kambham; Carol Wong; Fiona Kaper; Patrick Sutphin; Randall Nacamuli; Rendall Nacalumi; Michael Höckel; Quynh Le; Michael Longaker; George Yang; Albert Koong; Amato Giaccia
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

5.  Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

Authors:  Sandra E Ghayad; Julie A Vendrell; Ivan Bieche; Frédérique Spyratos; Charles Dumontet; Isabelle Treilleux; Rosette Lidereau; Pascale A Cohen
Journal:  J Mol Endocrinol       Date:  2008-11-04       Impact factor: 5.098

6.  Prognostic relevance of CCN3 in Ewing sarcoma.

Authors:  Bernard Perbal; Noureddine Lazar; Diana Zambelli; Jose Antonio Lopez-Guerrero; Antonio Llombart-Bosch; Katia Scotlandi; Piero Picci
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

7.  Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse.

Authors:  Mark Baguma-Nibasheka; Boris Kablar
Journal:  Dev Dyn       Date:  2008-02       Impact factor: 3.780

Review 8.  Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2008-03-11

9.  Signal transduction involved in CTGF-induced production of chemokines in mesangial cells.

Authors:  Sheng-Hua Wu; Chao Lu; Ling Dong; Zi-Qing Chen
Journal:  Growth Factors       Date:  2008-08       Impact factor: 2.511

10.  NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells.

Authors:  Rajeev Gupta; Dengli Hong; Francisco Iborra; Samantha Sarno; Tariq Enver
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

View more
  274 in total

1.  CCN3: the-pain-killer inside me.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2012-03-30       Impact factor: 5.782

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

3.  Genetic Analysis of Connective Tissue Growth Factor as an Effector of Transforming Growth Factor β Signaling and Cardiac Remodeling.

Authors:  Federica Accornero; Jop H van Berlo; Robert N Correll; John W Elrod; Michelle A Sargent; Allen York; Joseph E Rabinowitz; Andrew Leask; Jeffery D Molkentin
Journal:  Mol Cell Biol       Date:  2015-04-13       Impact factor: 4.272

4.  Wnt1 inducible signaling pathway protein 1 (WISP1) blocks neurodegeneration through phosphoinositide 3 kinase/Akt1 and apoptotic mitochondrial signaling involving Bad, Bax, Bim, and Bcl-xL.

Authors:  Shaohui Wang; Zhao Zhong Chong; Yan Chen Shang; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2012-02       Impact factor: 1.990

Review 5.  Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics.

Authors:  Himadri Patel; Pritish Nilendu; Devashree Jahagirdar; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cancer Biol Ther       Date:  2017-12-08       Impact factor: 4.742

Review 6.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis.

Authors:  Tsu-Yao Cheng; Ming-Shiang Wu; Kuo-Tai Hua; Min-Liang Kuo; Ming-Tsan Lin
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

7.  CCN2 as a novel molecule supporting energy metabolism of chondrocytes.

Authors:  Aya Maeda-Uematsu; Satoshi Kubota; Harumi Kawaki; Kazumi Kawata; Yoshiaki Miyake; Takako Hattori; Takashi Nishida; Norifumi Moritani; Karen M Lyons; Seiji Iida; Masaharu Takigawa
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

8.  Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.

Authors:  Ze Liu; Mandi M Hopkins; Zhihong Zhang; Chrystal B Quisenberry; Louise C Fix; Brianna M Galvan; Kathryn E Meier
Journal:  J Pharmacol Exp Ther       Date:  2014-12-09       Impact factor: 4.030

9.  CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer.

Authors:  Hyungjoo Kim; Seogho Son; Yunhyo Ko; Incheol Shin
Journal:  Oncogene       Date:  2021-03-10       Impact factor: 9.867

10.  Sonic advance: CCN1 regulates sonic hedgehog in pancreatic cancer.

Authors:  Andrew Leask
Journal:  J Cell Commun Signal       Date:  2012-12-20       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.